

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/048,016	01/28/2002	Per Antonsson	003300-903	1277
21839 7	590 02/27/2003			
BURNS DOANE SWECKER & MATHIS L L P POST OFFICE BOX 1404 ALEXANDRIA, VA 22313-1404			EXAMINER	
			SALIMI, ALI REZA	
,			ART UNIT	PAPER NUMBER
			1648	\mathcal{A}
			DATE MAILED: 02/27/2003	, [

Please find below and/or attached an Office communication concerning this application or proceeding.

. Office Action Summary

Application No. 10/048,016

Applicant(s)

Antonsson et al

Examiner

A. R. SALMI

Art Unit 1648



	The MAILING DATE of this communication appears	on the cover s	heet with	the correspondence address			
	for Reply						
	ORTENED STATUTORY PERIOD FOR REPLY IS SET	TO EXPIRE _	One	_ MONTH(S) FROM			
	THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the						
mailing	g date of this communication.		,	·			
- If NO	 If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. 						
- Any re	o to reply within the set or extended period for reply will, by statute, cause the oply received by the Office later than three months after the mailing date of t						
Status	d patent term adjustment. See 37 CFR 1.704(b).	•					
1)	Responsive to communication(s) filed on			·			
2a) 🗌	This action is FINAL . 2b) \square This act	tion is non-fina	al.				
3) 🗆	3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11; 453 O.G. 213.						
Disposi	tion of Claims						
4) 🗶	Claim(s) <u>1-28</u>			is/are pending in the application.			
4	4a) Of the above, claim(s)			is/are withdrawn from consideration.			
5) 🗆	Claim(s)			is/are allowed.			
6) 🗆	Claim(s)			is/are rejected.			
7) 🗆	Claim(s)			is/are objected to.			
8) 💢	Claims 1-28						
Applica	ation Papers						
9) 🗌	The specification is objected to by the Examiner.						
10) ☐ The drawing(s) filed on is/are a) ☐ accepted or b) ☐ objected to by the Examiner.							
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
11)	The proposed drawing correction filed on	i:	s:a)□ a	approved b) \square disapproved by the Examiner.			
	If approved, corrected drawings are required in reply	to this Office a	ction.				
12) The oath or declaration is objected to by the Examiner.							
Priority	under 35 U.S.C. §§ 119 and 120						
13) Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).							
a) All b) Some* c) None of:							
	1. Certified copies of the priority documents have been received.						
	2. Certified copies of the priority documents have been received in Application No						
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).							
*S	ee the attached detailed Office action for a list of the			eceived.			
14) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).							
a) The translation of the foreign language provisional application has been received.							
15) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.							
Attachm							
	tice of References Cited (PTO-892)	_		0-413) Paper No(s)			
2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)		5) Notice of Informal Patent Application (PTO-152) 6) Other:					
···ر_ ،	On Bloom Discussion Statement(s) (F10-1443) Paper NO(s).	o/ Uther:					

Art Unit: 1648

 $\hat{\lambda}^{1}$

DETAILED ACTION

The Art Unit location of your application in the USPTO has changed. To aid in correlating any papers for this application, all further correspondence regarding this application should be directed to Art Unit 1648.

Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1, 2, 21, 22, drawn to modified L1 human papillomavirus and method of treating.

Group II, claim(s) 1, 3, 4, 5, drawn to modified fusion protein papillomavirus L1 with a T cell epitope. (Please note if this group is selected further select one specie to be examined on the merits, and amend the claims accordingly, see below for explanation)

Group III, claim(s) 1, 3, 6-12, 27, 28, drawn to modified fusion protein papillomavirus L1 with a antibody epitope. (Please note if this group is selected further select one specie to be examined on the merits, and amend the claims accordingly, see below for explanation)

Application/Control Number: 10/048,016

Art Unit: 1648

Group IV, claim(s) 1, 13-15, drawn to modified fusion protein papillomavirus L1 with a L2 peptide. (Please note if this group is selected further select one specie to be examined on the merits, and amend the claims accordingly, see below for explanation)

Group V, claim(s) 1, 16, 17, drawn to polynucleotide. (Please note if this group is selected further select one sequence to be examined on the merits, and amend the claims accordingly, see below for explanation)

Group VI, claim(s) 1, 18, drawn to a vaccine.

Group VII, claim(s) 19, 20, drawn to polynucleotide coding for a carrier. (Please note if this group is selected further select one sequence to be examined on the merits, and amend the claims accordingly, see below for explanation)

Group VIII, claim(s) 23, 24, drawn to method of preventing human papillomavirus infection.

Group IX, claim(s) 25, 26, drawn to method of treating cancer.

The inventions listed as Groups I-IX do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: The invention of Group I is known in the prior art as evidence by Gissmann et al (WO 96/11272) wherein the reference teaches the product of modified L1 papillomavirus (see the abstract, and the claims). The cited evidence prove that the technical feature of Group I does not make a contribution over the prior art. Thus, the claims are not so linked by a special technical feature within the meaning of PCT Rule 13.2.

Art Unit: 1648

١,

This application contains claims directed to more than one species of the generic invention. These species are deemed to lack unity of invention because they are not so linked as to form a single general inventive concept under PCT Rule 13.1 so as to forma single inventive concept.

The species are as follows:

(1) antigens comprising tumor, (2) bacterial, (3) parasitic, (4) viral (5) auto-antigen, or (6) polynucleotide.

Applicant is required, in reply to this action, to elect a single species from the list above. The reply must also identify the claims readable on the elected species, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered non-responsive unless accompanied by an election. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

The species listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons: each of the above recited species have different structures and presumably render different effect.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Application/Control Number: 10/048,016

Page 5

Art Unit: 1648

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the

inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently

named inventors is no longer an inventor of at least one claim remaining in the application. Any

amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the

fee required under 37 CFR 1.17(I).

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner

should be directed to A. R. Salimi whose telephone number is (703) 305-7136. The examiner can

normally be reached on Monday-Friday from 9:00 Am to 6:00 Pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor,

James Housel, can be reached on (703) 308-4027. The fax phone number for this Group is (703)

305-3014, or (703) 308-4242.

Any inquiry of a general nature or relating to the status of this application or proceeding

should be directed to the Group receptionist whose telephone number is (703) 308-0196.

A. R. Salimi

2/27/2003

ALI R. SALMINE PRIMARY EXAMINE